A total of 9928 patients taking cimetidine and 9351 controls were recruited to a postmarketing drug surveillance study in Glasgow, Nottingham, Oxford, and Portsmouth. Takers were identified by the Prescription Pricing Bureau at Nottingham and by dispensing pharmacists at the other three centres. All but 1-2% of the takers and 16% of the controls were successfully followed up for one year during which hospital visits and deaths were recorded. Three hundred and seventy five of the cimetidine takers and 198 of the controls are known to have died. Most of the difference in mortality was accounted for by an excess among the takers of deaths from cancers of the oesophagus, stomach, colon, and lung; from neoplasms of the lymphatic and haematopoietic system; and from ischaemic heart disease, chronic liver disease, and accidents and poisonings. So far as can be assessed, however, none of these drug-
Introduction Cimetidine (Tagamet) was first marketed in late 1976 for the treatment of gastric acid related disease and soon became widely used (about 25 million patients have now taken the drug worldwide). As a new pharmacological entity, which could have effects on many body systems,' cimetidine was clearly an eminently suitable drug for an experimental postmarketing surveillance study. Accordingly, in 1977 we investigated the possibility of identifying about 10 000 takers of cimetidine (and a similar number of controls) in four centres (Glasgow, Nottingham, Oxford, and Portsmouth) with a view to monitoring hospital visits and deaths among them over at least 12 months. The study proved feasible and we have already outlined the methods used2 and reported our findings on gastric cancer. 3 We now describe the survey methods in more detail and present an analysis of the deaths occurring in patients taking cimetidine and in the controls during the initial 12 month follow up period.
Methods
Approval of the study was obtained from the Pharmaceutical Society of Great Britain, the Committee on Safety of Medicines, local medical committees, hospital medical staff committees, and individual pharmacists and general practitioners.
IDENTIFICATION OF TAKERS
In Nottingham cimetidine takers were identified by copies of prescriptions supplied by the Prescription Pricing Bureau. At the other three centres the names and addresses of takers and doctors, together with prescription details, were obtained on a form from the dispensing pharmacists, who were paid a small honorarium. Pharmacists were given a list of participating doctors to ensure that unauthorised information was not disclosed, although acceptance of the study by general practitioners (and pharmacists) was excellent. In all, 327 (9351) was smaller than that of takers largely because of local difficulties in recruitment at Glasgow. Subjects lost to follow up during the survey year amounted to 122% of the takers (varying from 066% to 200% at the different centres) and 166% of the controls (varying from 0 60' to 266% at the different centres). In addition, 64 controls who started taking cimetidine during the survey year were excluded from further analysis.
Of the subjects followed up for 12 months, 63% of the takers were men; male takers tended to be younger than female takers. Within the centres the proportion of male takers varied from 58% (Portsmouth) to 66% (Oxford) . The mean ages of the takers in Glasgow (men 47, women 53) were lower than the mean ages of those in the other centres (Nottingham, men 51, women 57; Oxford, men 55, women 57; Portsmouth, men 53, women 58). Table I compares the observed mortality during the 12 month follow up period in each centre with the mortality expected on the basis of national rates. Overall, the ratio of observed to expected deaths was 18 for the takers and 10 for the controls. A considerable variation was found in the mortality ratios from centre to centre-with Glasgow at the lower end of the range and Portsmouth at the upper end-both for takers and controls (table I) . This variation presumably reflects differences in the populations sampled at the various centres. In table II the deaths occurring among takers and controls are classified by underlying cause. There were several major differences between the two study groups. To assess their meaning we examined in detail all the available documentation about the individuals who died from the diseases showing the biggest variation.
Results

MORTALITY RATES
Carcinoma of the oesophagus (ICD 150) (expected mortality in takers at national rates 0 9 men, 0 4 women)-Six of the seven takers had had cancer diagnosed within two months of first taking cimetidine. The drug could not, therefore, have been responsible for the disease in these individuals but instead must have been given for symptoms caused by an undiagnosed cancer. The remaining patient, a 68 year old man with a 15 year history of gastric ulcer, hiatus hernia, and oesophagitis had a benign oesophageal stricture dilated, started taking cimetidine, and did not present for further investigation until eight months later when an invasive adenocarcinoma was diagnosed. He had taken an estimated 900 tablets of cimetidine before diagnosis.
Carcinoma of the stomach (ICD 151) (expected mortality in takers 2 9 men, 1 3 women)-Fourteen takers had the disease at or before the date of the first prescription, while another 26 were diagnosed (or died) within six months (25 within four months) of first receiving the drug. The remaining five takers were diagnosed (or died) 7, 10, 12, 15, and 24 months after the date of their first prescription. The relation between cimetidine and gastric cancer in our study is analysed in more detail in another paper3 (in which cases of gastric cancer diagnosed outside the survey year are also reported).
Carcinoma of the colon (ICD 153) (expected mortality in takers 19 men, 1 6 women)-Six takers had the disease before or at the time of the first prescription, while a further two were diagnosed within two months of starting to take the drug. One taker received about 950 tablets before diagnosis, 19 months after the first prescription, while another received about 1500 tablets over 26 months before the disease was diagnosed.
Carcinoma of the trachea, bronchus, and lung (ICD 162) (expected mortality in takers 12 3 men, 2-2 women)-Seventeen takers were known to have cancer of the lower respiratory tract before starting to take cimetidine, while a further seven were diagnosed within six months of first receiving the drug. The remaining 11 takers with cancer of the lung were first diagnosed more than six months after taking cimetidine (see table III).
Malignant neoplasms of lymphatic and haematopoietic systems (expected mortality in takers 1-6 men, 0-9 women)-The causes of death for the 15 takers were recorded as: malignant lymphoma, six; Hodgkin's disease, one; multiple myeloma, three; lymphosarcoma, three; plasma cell leukaemia, one; lymphoid leukaemia, one. Thirteen of these takers were known to have had their disease before starting to take cimetidine, the drug being prescribed to alleviate symptoms of the disorder or of its treatment (especially with corticosteroids). Of the remaining two takers, one was suspected of having a lymphoma of the stomach at the time cimetidine was first prescribed (the diagnosis being confirmed five months later), while the second was diagnosed at laparotomy 12 months after the first prescription and died three weeks after surgery.
Ischaemic heart disease (ICD 410-414) (expected mortality in takers 41 4 men, 18 4 women)-The difference in mortality from ischaemic heart disease between the takers and the controls (rates in the groups 8 0 per 1000 and 6 0 per 1000 respectively) was not statistically significant (p=0 15). Examination of the records did not show anything of note.
Diseases of the oesophagus, stomach, and duodenum and MINIPRINT TABLE II . gastrointestinal haemorrhage (ICD 578) (expected mortality in takers 1-2 men, 0 7 women)-Four takers died from a gastric ulcer (haemorrhage in three, perforation in one), four from a duodenal ulcer (haemorrhage in three, perforation in one), one from a perforated oesophageal ulcer, one from gastritis (haemorrhage) (diagnosed at necropsy), one from a peptic ulcer of unknown site, and one from a gastrointestinal haemorrhage probably from an oesophageal ulcer or oesophagitis secondary to a hiatus hernia. Survival varied from one day to 30 months after the first prescription for the drug. Six subjects had not taken cimetidine for at least six months before death. In none of the others was there any evidence that death followed sudden withdrawal of the drug except perhaps for an 82 year old woman who had a fatal haematemesis 24 days after stopping the drug; she was, however, taking indomethacin and other analgesics at the time of death. We have no information about the taker who had a perforated oesophageal ulcer, but we suspect that only four deaths (one in a 90 year old man with multiple pathology, including cancer of the kidney) occurred during treatment with cimetidine. Chronic liver disease and cirrhosis (ICD 571) (expected mortality in takers 0 5 men, 0-25 women)-Most of these takers were given cimetidine as part of the management of the terminal stages of cirrhosis of the liver, identified as alcoholic in five and established for many months or years in all. The number of tablets prescribed did not exceed 200 for any taker. In no case was there any suggestion of a causal link between cimetidine treatment and the disease, although we cannot, of course, prove that the drug did not exacerbate an already precarious clinical condition.
Accidents, poisoning, and violence (ICD 800-999, E codes) (expected mortality in takers 3-8 men, 2-0 women)-The deaths in takers were the result of: overdose of drugs (not cimetidine) or alcohol, or both, six; drowning, two; road traffic accident, two; unspecified railway accident, one; carbon monoxide poisoning from a fire, one; air embolism, one; and postoperative wound infection, one. Five of the takers who were poisoned or drowned had a history of depression or alcohol and drug abuse, or both, as did the taker killed in the fire. We can be sure only that two of the 14 subjects were taking cimetidine in the weeks before their death.
Other causes of death-The special groups of causes of death detailed above together account for 226 fatalities among the cimetidine takers and 82 among the controls. In aggregate the remaining causes of death accounted for 149 fatalities (15 2 per 1000) among the takers and 116 (12 7 per 1000) among the controls, a small difference which is not statistically significant.
SMOKING AND DRINKING HABITS
In total, 503 questionnaires were sent to takers and 504 to controls; response rates were 80% and 76% respectively. Questions were asked both about present habits and about habits five years previously. We hoped that the responses to questions on the latter might give some indication of the subjects' habits before the onset of the disease leading i to cimetidine treatment. 
Discussion
In recent years several different approaches to the surveillance of newly marketed drugs have been sugested. [5] [6] [7] [8] The approach that we finally adopted was similar to that proposed by Lawson and Henry.7 On the whole we were satisfied with the outcome. Our study shows that it is possible to gain the cooperation of large numbers of doctors and pharmacists (including those working in retail practice), to recruit thousands of takers of the drug of interest together with controls, and to record major illnesses and deaths occurring over one year with minimal loss to follow up. We are, of course, aware that studying a sample of 10 000 drug takers offers only a modest likelihood that rare adverse reactions will be detected and that the choice of a suitable group for comparison is extremely difficult. These problems are, however, common to the other new approaches to drug surveillance that have been proposed. A more important limitation of our method is its dependence on skilled research assistants for the collection of much of the data. This means that costs are high and that only widely used drugs may be studied since each research assistant can cover only a restricted geographical area. At the same time the use of dedicated personnel ensures that accurate data are collected and that follow up rates are satisfactory.
The data shown in table II are worrying at first glance, but detailed analysis shows that the different drug-disease associations do not, so far as we can tell, represent adverse effects of cimetidine treatment. Instead, in most instances, the associations result from cimetidine being used, knowingly or unknowingly, for treating the symptoms of various diseases-for example, cancer of the oesophagus and of the stomach, malignant lymphoma, peptic ulcer, and cirrhosis-or for alleviating adverse effects of other drug treatments-for example, corticosteroids, non-steroidal anti-inflammatory agents, and radiotherapy.
The large number of excess deaths from lung cancer among the takers could be explained by habitual heavy smoking were it not for the small difference in smoking habits between takers and controls actually recorded by the special questionnaire. Nevertheless, the fact that deaths from pneumonia and chronic obstructive airways disease were also commoner among the takers than the controls suggests that, whatever the responses on the questionnaire, takers were in fact heavier smokers than controls. Having said this, it appears that symptomatic treatment explains most of the association between lung cancer and cimetidine because the drug was given after the diagnosis of lung cancer in 17 cases. In addition, five takers were first found to have lung cancer at the time of diagnosis of peptic ulcer, a direct consequence of intensively investigating such patients.
The difference in mortality from ischaemic heart disease between takers and controls was small and could have been due to chance. In some cases, however, cirfietidine may have been prescribed for cardiac pain in the belief that it was of gastric origin.
We found no evidence, as has been suggested, 9 that withdrawal of cimetidine is sometimes followed by severe and occasionally fatal relapse of peptic ulcer disease. Instead, in view of the widespread use of cimetidine in gastric emergencies, we were surprised to find so few deaths attributed to peptic ulcer among the takers.
When examining the deaths from accidents and poisonings, we found no evidence that cimetidine induced mental or physical disability, although there were two road accidents and one unspecified railway accident in this group. Generally, cimetidine was apparently often being given for the treatment of diseases related to alcohol or drug abuse, which themselves tend to lead to deaths from violence.
Our special postal survey did not indicate a large difference in smoking or drinking habits between takers and controls, but our method of inquiry was crude (especially as we were most interested in past rather than present habits) and we do not know the habits of those who died. Certainly we have evidence, both from the deaths occurring from chronic liver disease and from those occurring from accidents and poisonings, that heavy drinkers were attracting cimetidine prescriptions and thereby producing non-causal associations in our data.
We conclude (a) that our method of postmarketing surveillance is both feasible and useful; (b) that the interpretation of data obtained from studies such as ours is complex (it would be very easy to jump hastily to the wrong conclusions); and (c) that we have been unable to find any evidence of fatal adverse effects of cimetidine in a study of nearly 10 000 subjects taking the drug. We are analysing our morbidity data and are continuing to identify deaths among takers soon after they occur with the help of the NHS central registries.
